Abstract Background and objectives The MeMed BV® test distinguishes bacterial from viral infections by integrating circulating levels of TRAIL, IP-10, and CRP into a likelihood score. Pre-COVID studies reported high diagnostic accuracy in respiratory infections, but evidence in adults hospitalized with SARS-CoV-2 is sparse. To evaluate the ability of MeMed BV to identify hospitalized COVID-19 patients who could be safely managed without antibiotics. Methods We included adults with PCR-confirmed SARS-CoV-2 infection from two prospective Norwegian cohorts (October 2020–April 2023). The reference standard for true viral infection was a composite safety outcome: 30-day survival, no readmission within 30 days, and no antibiotic exposure before, during, or after hospitalization. MeMed BV performance was assessed using sensitivity, specificity, predictive values, and area under the ROC curve (AUC). Results Of 90 patients, 28 (31%) met the reference standard for safe antibiotic avoidance. Median MeMed BV scores were 38 (IQR 1–66) in the safely managed group versus 96 (IQR 78–99) in others (P 0.001). Sensitivity for identifying safe antibiotic avoidance was 50.0% (95% CI 32.6–67.4), specificity 88.7% (95% CI 78.5–94.4), PPV 66.7%, NPV 79.7%, and AUC 0.69 (95% CI 0.59–0.80). Patients safely managed without antibiotics misclassified as bacterial/equivocal had markedly lower TRAIL (median 38 versus 177 pg/mL, P 0.001) and higher CRP. Conclusions In hospitalized adults with COVID-19, MeMed BV showed reasonable specificity but limited sensitivity for identifying patients who could safely avoid antibiotics, with performance considerably lower than that observed in pre-COVID studies. These findings highlight the need for context-specific validation of host-response diagnostics.
Thelle et al. (Wed,) studied this question.